Shares of Merck (NYSE:MRK) traded marginally higher on Friday after falling from a high of $119.38 from the past seven ...

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...

Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...

Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

We recently compiled a list of the 7 Undervalued Blue Chip Stocks To Buy Right Now. In this article, we are going to take a ...